By Shawn Hauser
May 29, 2024
We are at a historic and critical moment for cannabis reform, as the DOJ and HHS/FDA have proposed rescheduling cannabis to Schedule III. The DEA is accepting public comments until July 22, 2024 via the Federal eRulemaking Portal, so now is the time to take action and make your voice heard!
Dec 21, 2023
Shawn Hauser recently joined the “One Minute With…” podcast hosted by Jacques Santucci of Opus Consulting to discuss Vicente LLP’s history with cannabis legalization, the recent recommendation by the HHS to reschedule marijuana to a Schedule III drug and what this means for the future of federal drug policy reform. Listen now!
By Shane Pennington
Apr 4, 2023
Cannabis researchers can study the dispensary strains and products people are actually using around the country right now... without violating federal law… and without Congress lifting a finger. Read this article for two simple tricks to do so.
By Jason Adelstone
Mar 15, 2023
In its 2022 report, the International Narcotics Control Board (INCB) argues that legalizing the non-medical and non-scientific use of cannabis has failed to achieve the benefits to society that were intended through such legalization. In its attempt to deliver evidence of this failure, INCB instead provides ample evidence to the contrary—that legalization and regulation work. Read this insight for Vicente LLP’s response to the annual report of the INCB.
By Shane Pennington
Mar 1, 2023
How TGA's rescheduling of psilocybin and MDMA shines a bright light on DEA delinquency